Last reviewed · How we verify
PF-06873600 — Competitive Intelligence Brief
discontinued
PF-06873600 tablet for oral dosing
Oncology
Live · refreshed every 30 min
Target snapshot
PF-06873600 (pf-06873600) — Pfizer Inc.. PF-06873600 tablet for oral dosing
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PF-06873600 TARGET | pf-06873600 | Pfizer Inc. | discontinued | PF-06873600 tablet for oral dosing |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (PF-06873600 tablet for oral dosing class)
- Pfizer Inc. · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PF-06873600 CI watch — RSS
- PF-06873600 CI watch — Atom
- PF-06873600 CI watch — JSON
- PF-06873600 alone — RSS
- Whole PF-06873600 tablet for oral dosing class — RSS
Cite this brief
Drug Landscape (2026). PF-06873600 — Competitive Intelligence Brief. https://druglandscape.com/ci/pf-06873600. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing